A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial
Cancer Cell · 2024-10 · 42 (10) · 1747-1763.e7
DOI: 10.1016/j.ccell.2024.09.008 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer Cell, 2024-10. Verfasst von Xiaobin Shang und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Minimally Invasive Esophageal Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for …. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Tianjin Municipal Health Commission, Beijing Xisike Clinical Oncology Research Foundation, Tianjin Municipal Science and Technology Bureau.
Themen: Onkologische Pflege
Abstract (Originalsprache)
In this phase II study, 47 patients with locally advanced, resectable esophageal squamous cell carcinoma (ESCC) received three cycles of pembrolizumab plus chemotherapy, followed by Da Vinci robot-assisted surgery. The primary endpoints were safety and major pathological response (MPR). Key secondary endpoints included complete pathological response (pCR) and survival. No grade ≥3 adverse events or surgical delays occurred during neoadjuvant therapy. Among 46 patients studied for efficacy, the MPR and pCR rates were 72% and 41%, respectively. After a median follow-up of 27.2 months, the 2-year overall survival (OS) and disease-free survival (DFS) rates were 91% and 89%, respectively. Expansion of TRGC2+ NKT cells in peripheral blood correlated with neoadjuvant treatment effectiveness, which was validated by in vitro organoid experiments and external cancer datasets, and its functional classification and mechanism of action were further explored. These findings show preoperative pembrolizumab plus chemotherapy is a promising therapeutic strategy for resectable ESCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Minimally Invasive Esophageal Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Cli…
- The Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tia…
- Cancer Molecular Diagnostics Core, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Cen…
- Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Ca…
- Department of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai, China.
- Key Laboratory of Cancer Immunology and Biotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China;…
Förderung
- Tianjin Municipal Health Commission
- Beijing Xisike Clinical Oncology Research Foundation
- Tianjin Municipal Science and Technology Bureau
Zitieren
APA
Shang, X., Xie, Y., Yu, J., Zhang, C., Zhao, G., Liang, F., Liu, L., Zhang, W., Li, R., Yu, W., Yue, J., Chen, C., Duan, X., Ma, Z., Chen, Z., Xiong, Y., Yang, F., Xiao, J., Zhang, R., …, & Jiang, H. (2024). A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial. Cancer Cell, 42(10), 1747-1763.e7. https://doi.org/10.1016/j.ccell.2024.09.008
Vancouver
Shang X, Xie Y, Yu J, Zhang C, Zhao G, Liang F, et al. A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial. Cancer Cell. 2024;42(10):1747-1763.e7. doi:10.1016/j.ccell.2024.09.008
BibTeX
@article{Shang2024,
author = {Shang, Xiaobin and Xie, Yongjie and Yu, Jinpu and Zhang, Chen and Zhao, Gang and Liang, Fei and Liu, Liang and Zhang, Weihong and Li, Runmei and Yu, Wenwen and Yue, Jie and Chen, Chuangui and Duan, Xiaofeng and Ma, Zhao and Chen, Zuoyu and Xiong, Yanjuan and Yang, Fan and Xiao, Jianyu and Zhang, Rui and Liu, Pengpeng and Cheng, Yanan and Cao, Fuliang and Guo, Feng and Liu, Guoyan and Meng, Bin and Zhou, Dejun and Sun, Yan and Ren, Xiubao and Yu, Jun and Hao, Jihui and Jiang, Hongjing},
title = {A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial},
journal = {Cancer Cell},
year = {2024},
volume = {42},
number = {10},
pages = {1747--1763.e7},
doi = {10.1016/j.ccell.2024.09.008}
}
EUVIMED